We assessed novel disability-based parameters and neuropathological features of the P0 [180][181][182][183][184][185][186][187][188][189][190] peptide-induced model of experimental autoimmune neuritis (EAN) in C57BL/6 mice. We show that functional assessments such as running capacity provide a more sensitive method for detecting alterations in disease severity than a classical clinical scoring paradigm. We performed detailed ultrastructural analysis and show for the first time that tomaculous neuropathy is a neuropathological feature of this disease model. In addition, we demonstrate that ultrastructural assessments of myelin pathology are sufficiently sensitive to detect significant differences in both mean G-ratio and mean axon diameter between mice with EAN induced with different doses of pertussis toxin. In summary, we have established a comprehensive assessment paradigm for discriminating variations in disease severity and the extent of myelin pathology in this model. Our findings indicate that this model is a powerful tool to study the pathogenesis of human peripheral demyelinating neuropathies and that this assessment paradigm could be used to determine the efficacy of potential therapies that aim to promote myelin repair and protect against nerve damage in autoimmune neuritides.
INTRODUCTION
Patients with autoimmune-mediated inflammatory disease of the peripheral nervous system (PNS) present with a wide range of symptoms, from mild tingling and sensory loss, to severe debilitating paralysis and in some cases death as a consequence of severe autonomic neuropathy. The most frequently encountered forms of these diseases are GuillainBarré syndrome (GBS), which can present as acute inflammatory demyelinating polyradiculoneuropathy, acute motor axonal neuropathy, acute motor sensory axonal neuropathy and Miller Fisher Syndrome (1) , and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) (2) (3) (4) . The pathogenesis of GBS and CIDP are believed to be autoimmune reactions directed against the myelin sheath, causing myelin injury and demyelination in the PNS (1, 3) . Damage to axons can occur in these conditions that results in chronic functional loss with approximately 25% of patients experiencing permanent neurological functional deficits (5, 6) .
Experimental autoimmune neuritis (EAN) is a widely used animal model of peripheral demyelinating diseases (7) (8) (9) (10) . It has provided the basis for our current understanding of pathogenesis of these diseases and for developing novel interventions for their treatment. EAN can be induced in rabbits (10) and in small rodents including rats (8) and mice (7, 9, 11) . The traditional induction paradigm using the P2 protein peptide 57-81 (P2 57-81 ) results in disease in the susceptible SJL mouse strain; other strains such as BALB/C and C57BL/6 mice are relatively resistant (11) . Sensitization paradigms using either the stronger neuritigenic antigens, that is, P0 [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] (7) , or P0 106-125 (9) , delivered in adjuvant and combined with the injection of pertussis toxin (Ptx), however, can induce EAN in C57BL/6 mice. While it is known that Ptx is required for the induction of P0-mediated EAN in C57BL/6 mice (7), and that Ptx can modulate the immune response to neuroantigens injected with Freund's adjuvant (12) , the effects of varying the dose of Ptx in P0-mediated EAN have not been investigated.
EAN in mice has been assessed using a number of measures including clinical scores, nerve conduction velocity, myelin protein expression, and immune cell profiles (7, 9, 13) . In human disease, a significant emphasis is placed on evaluating specific functional measures such as of running and gait, and detailed ultrastructural analysis of nerve pathology (14) . However, the parameters of functional capacity such as running efficiency, gait features, and the extent of myelin damage via ultrastructural analysis have not been examined thoroughly in murine P0 peptide-induced EAN models.
In this study, we evaluated the disease progression and functional capacity in the C57BL/6 mice EAN model using multidisciplinary approaches incorporating a comprehensive clinical scoring paradigm, a functional running test, and gait width analysis and detailed ultrastructural assessment of myelin pathology. We chose the P0 [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] -induced model because it is described as producing more subtle clinical signs than other P0 peptide-induced EAN models (9) . Our data show that EAN severity and progression are concordant with gait function deficiency and the extent of myelin damage. We show that a simple running test can detect weakness of running capacity and indicate disease severity in a highly sensitive manner, and that EAN mice display significant functional deficits including a failure in the ability to complete a simple running task and a significant hind limb gait widening compared with healthy controls. Importantly, while limited recovery was observed over the later course of EAN disease via clinical scoring, these functional deficits occur over a prolonged period and no recovery in either running ability or in hind limb gait width was observed over the examined period, indicating that there is lasting neuronal damage. We also found a dosedependent effect of Ptx on EAN severity and functional deficits as well as myelin pathology, regardless of the routes of Ptx administration. Together, our results provide new insight to our understanding of the murine EAN model and its application for studying the pathogenesis of peripheral demyelinating neuropathy and possible mechanisms of actions of current and future treatment strategies.
MATERIALS AND METHODS

Animals and Reagents
Male C57BL/6 mice, 6-8 weeks old, were purchased from the Animal Resource Center (Perth, Australia), and housed at the Animal Facilities of the Biomedical Education Academic Centre, Florey Institute of Neuroscience and Mental Health Research, the University of Melbourne. All chemicals were obtained from Sigma-Aldrich (St. Louis, MO), unless otherwise indicated.
EAN Induction
Twenty male mice were immunized 2 times (Days 0 and 8 post-induction [p.i.]) by subcutaneous injection placed in between the scapulae of 50 ll of an inoculum containing 50 lg of P0 peptide 180-199 (P0 [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] 
Clinical Scoring
The most commonly used methodology to assess behavioral deficits in the mouse model of EAN is by a clinical scoring paradigm (7, 9, 11) . In this study, we did not observe ascending paralysis characterized by initial tail weakness that progressively ascends to the forelimbs as the disease worsens. In fact, the disease presentation was unique to each animal; for example, we observed animals that developed limb paresis but no significant tail weakness; some mice showed hind limb paresis with significant ataxia such as reverse walking (Supple mentary Data Video S1); and in some mice there was significant limb and tail paresis but no apparent ataxia. In order to assess the range of clinical deficits observed and score them more precisely, we used the scoring paradigm outlined in Table. An investigator blinded to the experimental conditions conducted all clinical scores.
Functional Testing and Gait Assessment
Using the DigiGait system (eMouse specifics, Inc., Framingham, MA), mice were videoed running on a transparent treadmill (15, 16) . A simple running task in which mice were set to complete a 36-second run at a treadmill speed of 15 cm/s was designed. Mice that could not maintain running for the 36-second interval was deemed as failing. Videos were captured during the running task and gait parameters were subsequently analyzed using the DigiGait 8 V R software (eMouse specifics). Mice were tested with the running task every 3 days; the gait parameters analyzed were hind limb and forelimb gait width distance during running. Gait analysis required that mice complete 10 successive steps with no interruption. If the mouse failed the running task prior to completing 10 successive steps, that run was not used for gait analysis. It typically took 15-20 seconds running time for mice to complete 10 continuous uninterrupted steps successfully and the 36-second time period for the running task was selected because it represented approximately double this running time.
Histology and Assessment of Myelin Pathology
All animals were transcardially perfused with 0.01 M-MT PBS followed by 4% paraformaldehyde. The sciatic nerve was dissected out, with the branch point of the tibial and fibular/peroneal division used as a landmark; a 2-mm segment of the nerve immediately proximal to this branch point was sampled. All tissues were post-fixed in Karnovsky's fixative followed by osmium tetroxide and processed for resin embedding, as previously described (17, 18) . Transverse semi-thin sections (0.5 lm) were cut and stained with toluidine blue. To identify areas of myelin pathology, all sections were first deidentified and imaged using a 20Â objective with all images captured using the same settings (Zeiss AzioVison V R , Oberkochen, Germany). Next, the de-identified images were subject to over/under threshold analysis using Fiji/ImageJ software (ImageJ 1.50i NIH, Bethesda, MD), with cross-sectional areas greater than 1500 lm 2 assessed to have over 50 threshold (using the standard pixel scale) identified as areas of myelin pathology. These regions were subsequently imaged at high power using a 100Â lens. All G-ratio analysis and quantification of myelinated axon diameters were performed on images taken at 1000Â magnification using a 100Â optical lens (19, 20) . All groups consisted of a minimum 3 sampling 300-500 axons for the G-ratio (axonal diameter/outer leaf myelin diameter) and axonal diameter data (a minimum of 70 myelinated axons per animal) were used for individual means. An operator blinded to the experimental conditions performed all data acquisition and analysis. Fiji/ImageJ software using the ROI function and measurement tools was used to trace and measure the circumferences of the myelin membranes and of the axons. The diameter for each was back calculated from the circumference traces to give the diameter measurements used in the Gratio calculation. In addition, ultrathin sections of sciatic nerve were imaged using an election microscope as previously described (17, 18) .
Statistical Analysis
Differences between pairs of groups for clinical scores were tested by Student t-test (two-tailed) and Mann-Whitney's U-test using a significance set at p < 0.05. In addition, repeated measures 2-way ANOVA testing was used to determine the interaction between dose and time with significance set at p < 0.05. Repeated measures 2-way ANOVA was utilized when assessing running time failure assessments; significance was set at p < 0.05. Differences in mean G-ratios and mean axon diameters were tested using 1-way ANOVA with Tukey's multiple comparisons tests; each group was comprised of mean values of at least 3 animals with a minimum of 70 axons/myelin sheaths sampled from each (mean values for individuals were grouped to avoid the analysis of technical replicates). Linear regression analysis was performed for Gratio and limb gait width analyses; significance was set at p < 0.001 for both. All statistical testing was performed using Graph Pad Prism 6 software (La Jolla, CA).
RESULTS
Functional Testing Identifies Reduced Running Capacity and Increased Hind Limb Gait Width as Novel Disability-Based Parameters of Murine EAN
C57BL/6 mice with EAN displayed significant clinical deficits compared with control mice, as assessed by clinical scores (Fig. 1A) . To investigate whether simple behavioral testing could reveal greater insight into functional deficits that are sustained in this EAN model, we used the DigiGait V R video recording running treadmill and software analysis system. Animals were put though a simple running task and assessed for running capability. Mice with EAN progressively declined in their ability to perform the running task with time, as demonstrated by an increased number of successive failures of the required task (Fig. 1B) . In addition, as the disease progressed, the mice displayed significantly reduced time to failure on the running test (Fig. 1C) . No control mouse consecutively failed the running task and there was a 100% completion rate at the end stage of the assessment period. Mice with EAN demonstrated failure in the running task as early as Day 6 p.i. (Fig. 1B) . Interestingly, Day 6 represents a time when clinical scores, as determined by the degree of abnormality observed during spontaneous walking, are still very mild (Fig. 1A ). There was some recovery in clinical scores after from Day 40 p.i. (Fig. 1 ), but no recovery in the capacity to run was observed over the disease course for any of the mice assessed (Fig. 1B, C) .
In addition to assessing running capability, the DigiGait V R system allowed us to assess gait functionality by capturing information about hind limb and forelimb gait widths during treadmill running. Regression analysis demonstrated a significant association between increased hind limb gait width and EAN progression (R 2 ¼ 0.312; p < 0.0001 (Fig. 1D ). In contrast, this was not observed in healthy control mice (Fig. 1D ). Further testing revealed that the slopes were significantly different between healthy control and EAN mice (p < 0.05), and repeated measures 2-way ANOVA using Sidak's multiple comparison testing revealed significant mean gait widths between healthy control and EAN mice from Day 20 to 30 p.i. Interestingly, no significant association for forelimb gait widening against time during the course of disease was detected between EAN and healthy control mice. Consistent with the running task assessments (Fig. 1B, C) , we observed no recovery in hind limb gait width for any of the mice with EAN (Fig. 1D ).
Differences in EAN Severity Result from Altering the Doses of Ptx during Induction
It has been shown previously that Ptx administered i.v. has an adjuvant effect upon the incidence of P0 180-199 peptideinduced EAN in male C57BL/6 mice (7). To investigate whether Ptx affects EAN disease profile and severity in a dose dependent manner, we induced EAN in separate high and low dose groups. Both high and low Ptx doses were injected mice either i.p. or i.v. We found that all mice in each group exhibited classical clinical deficits (Supplementary Data Fig. S1 ). However, mice that received the low dose of Ptx during EAN induction displayed significantly lower mean Table. (B) Percentage of mice that completed the running task over the course of clinical scores during early and end stages of the disease course versus the high dose group ( Fig. 2A, B) . Together this suggests that halving the dose of Ptx used during the EAN induction paradigm altered the propensity for disease progression and influenced end stage clinical scores but did not alter peak disease severity ( Fig. 2A, B) . There was no significant difference in mean severity scores between the i.v. and i.p. delivery paradigms (Fig. 2C, D) .
Running Capacity is a Highly Sensitive Measure of Disease Severity
We next examined whether functional testing could discriminate the effects of varying the dose of Ptx during EAN induction. Unlike the subtle effect observed for clinical scores, the dose of Ptx had a profound effect on the ability of the mice to complete a single running task. Irrespective of the Ptx delivery method, mice that received a high dose of Ptx failed the running task substantially earlier in the progression of EAN, compared with mice that received the low dose of Ptx (Fig. 3A, B) . Mice that received the high dose of Ptx began failing the running task from Day 6 p.i. versus mice that received the low dose of Ptx, which only demonstrated running task failure from 23 days p.i. (Fig. 3A, B) . Concordant with this finding there was a significant reduction in average running times, as measured by 2-way ANOVA analysis, earlier in the high dose versus low dose groups irrespective of the Ptx delivery method (Fig. 3C, D) .
We next evaluated whether limb gait width analysis could be used to identify the effects of varying the dose of Ptx during EAN induction. Irrespective of the Ptx dose or the delivery method, all mice with EAN had significant increases in hind limb gait width as the disease progressed but there was no significant difference in hind limb gait width and time between the high dose Ptx and low dose Ptx groups (Fig. 4A, B) . This indicates that long lasting functional deficits are sustained in both groups and that the dose of Ptx influenced the onset of the disease (measured by task running failure [ Fig. 3] ), but not the end stage hind limb gait widths (Fig. 4A, B) . We did not observe a significant association between fore limb gait width and time p.i. for any of the groups analyzed (Fig. 4C, D) .
Remyelination, Dysmyelination and Tomaculous Neuropathy are Features of P0 180-190 -Induced EAN and are Influenced by the Ptx Dose During Disease Induction Previous work using immunohistochemistry has shown that the P0 180-199 induced EAN mice display qualitative changes in the expression of myelin proteins such as myelin basic protein in their sciatic nerves, (7) . However, it is currently unknown whether and to what extent myelin ultrastructure is affected in this EAN model. By electron microscopy, we observed areas of thinly myelinated axons, indicating remyelination in all animals with EAN compared with healthy control mice of the same sex and age at Day 54 p.i. (Fig. 5A-C) . In all mice with EAN, we identified the dysmyelinated axons with myelin debris in close proximity, perhaps indicating ongoing pathology, or a failure of remyelination (Fig. 5D-F) . Moreover, all mice with EAN had classical tomaculous myelin swellings and tomaculous neuropathy; these findings appeared to be more common in the high dose Ptx groups. Interestingly, we often observed axon abnormalities including enlarged mitochondria within axonal segments, in particular adjacent to tomaculous myelin (Fig. 5G-I) .
To quantify the extent of demyelination, we analyzed myelin thickness of myelinated axons in affected regions by calculating G-ratios of individual axons in mice with EAN and randomly sampled healthy control mouse tissue samples. Irrespective of the Ptx delivery method (i.p. vs i.v.), all mice induced with EAN displayed significantly higher mean G-ratios compared with healthy control mice of a similar age (Fig. 6A) , thus indicating remyelination. Interestingly, mean G-ratios were significantly greater in animals that had received a high versus low Ptx dose (Fig. 6A) . Because peripheral hypomyelination and tomaculous neuropathy are associated with a reduction in axon diameter (21, 22) , we assessed whether there was an effect on axonal calibers in mice with EAN versus controls. We identified significant decreases in mean axon diameter for mice that received a high dose compared with both low dose Ptx and healthy control cohorts (Fig. 6B) . Interestingly, we observed no significant difference in mean axonal caliber between low dose Ptx groups and healthy controls (Fig. 6B) . These data indicate that detailed ultrastructural analysis is a sensitive way for discriminating dose-dependent effects of Ptx upon axonal diameter and that more severe pathology occurs in the high dose Ptx groups.
To assess the changes in G-ratio in relation to axon diameter in detail, we plotted G-ratios against axon diameter and developed regression lines for all groups. There were significant differences in the slopes and Y-intercepts between EAN groups and age-matched controls (p < 0.0001), demonstrating that all mice with EAN had thinner myelin relative to their axonal diameters (Fig. 6C, D) . For both high and low dose Ptx groups, the slope coefficients were significantly lower, concomitant with elevated Y intercepts, indicating that thinner myelin is more prevalent for smaller diameter axons (Fig. 6C, D) . In addition, animals in the high Ptx dose group had significantly larger Y-intercepts and smaller slope coefficients compared with those in the low dose Ptx cohort. This indicates that a greater number of axons were remyelinated, and thus the extent of demyelination for the high dose 
Ptx group was significantly greater than that in the low dose Ptx group (Fig. 6C, D) . Our findings clearly show that detailed ultrastructural analysis can identify the dose dependent effect of Ptx upon the extent of myelin pathology in EAN.
To examine the extent of myelin damage further, we plotted the frequency distributions of G-ratio scores (Fig. 6E ) and frequency distribution plots of axon diameters (Fig. 6F) . The data showed a clear right shift (higher G-ratios) in the distribution of G-ratios for all EAN cohorts compared with healthy controls (Fig. 6E) , indicating thinner myelin. Consistent with this finding, the frequency distribution plots of axon diameters showed a narrower distribution in axonal calibers in animals with EAN compared with controls, indicating reduced axonal sizes (Fig. 6F ).
DISCUSSION
Utilizing a multidisciplinary approach, evaluating running capacity and gait widths combined with an extensive assessment of myelin histopathology, we have comprehensively characterized the P0 180-190 peptide-induced model of murine EAN in C57BL/6 background mice. For the first time, we identify novel disability-based parameters (e.g. running failure and hind limb gait widening) as features of the disease. In addition, we show clear evidence that remyelination, axon pathology, and tomaculous neuropathy are hallmark histopathological findings in this EAN model. Our combined approach can be used as a highly sensitive paradigm capable of discriminating different levels of disease severity in this EAN model.
Evaluating Running Capacity and Hind Limb Gait Widths Reveals Novel Disability-Based Parameters as Features of Murine EAN
We demonstrate that while clinical scoring is sufficient to measure disease progress and severity, it is insensitive . EAN clinical scores were assessed as described in Table. to detect some key long-term functional deficits, in particular after the peak of clinical disease. Indeed, for the first time we found that 80% of all mice with EAN failed the running task during the entire disease course, and that all EAN mice sustained lasting functional deficits, which worsened at subsequent days p.i. This was demonstrated by a complete lack of any functional recovery once the mice failed in the running task. Subsequent to initial running task failure, there was also a significant progressive decrease in running capacity with time p.i. This was evidenced by successively shorter running durations prior to running task failure at subsequent evaluations over the disease course. Thus, the C57BL/6 mice sustain increasing functional deficits up to 54 days p.i. Evaluating gait width parameters enabled regression analysis that revealed a significant association between hind limb gait widening and time. We observed no recovery in hind limb gait width, supporting the notion that the mice sustained functional deficits that worsened over disease course. This marks another sustained disability-based parameter that is not identified by clinical scoring alone. Interestingly, there was no significant association between forelimb width distance and the progression of EAN, providing some evidence that the fore limbs are not affected as severely as the hind limbs in this model. 
Functional Running Testing Can Detect Differences in EAN Severity due to Varying the Dose of Ptx Used for Induction
In humans with peripheral demyelinating diseases, running is one of the most severely affected functions and one of the most difficult to restore (14) . In this study, we show that a simple running test can detect weakness and indicate disease severity in a highly sensitive manner in mice with EAN. At 6 days p.i., most animals displayed very minor clinical scores ( 1) and no significant difference was detected between high and low dose Ptx groups using clinical scoring ( Fig. 2A, B) , functional running capacity assessment clearly discriminated between 2 Ptx groups at this early disease stage (Fig. 3) . Thus, assessment of running capability (through assessment of the running time prior to running task failure) allowed discrimination between mice that had been induced with a high dose versus low dose Ptx (Fig. 3) . In addition, mice induced with the high dose of Ptx failed in the running task substantially earlier than mice induced with the low Ptx dose, clearly showing that Ptx plays a key role in the initiation of disease manifestations. Collectively, our data suggest that clinical scoring alone may not be sufficiently sensitive to detect differences in disease severity early in the disease course. Thus, classical clinical scoring in combination with the functional assessment provides a more sensitive and comprehensive measurement of EAN progression. shows that hind limb distance increases for mice during the running task throughout the EAN disease course of both Ptx doses groups (R 2 high dose ¼ 0.312, R 2 low dose ¼ 0.315, p < 0.001 for both). There is no significant difference for the slopes or intercepts between the high and low dose groups. (B) Linear regression analysis for i.v. Ptx-injected mice shows that hind limb distance increases for mice during the running task throughout the course of EAN in both Ptx dose groups (R 2 high dose ¼ 0.509, R 2 low dose ¼ 0.317, p < 0.001 for both). There is no significant difference for the slopes and intercepts between 2 doses groups. (C) Linear regression analysis for i.p. Ptx-injected mice shows that forelimb distance does not increase for mice during the running task throughout the course of EAN (R 2 high dose ¼ 0.045, R 2 low dose ¼ 0.13, p > 0.01 for both). There is no significant difference for the slopes between 2 doses groups. (D) Linear regression analysis for i.p. Ptx-injected mice shows that forelimb distance does not increase for mice during the running task throughout the course of EAN (R 2 high dose ¼ 0.049, R 2 low dose ¼ 0.15 m p > 0.01 for both). There is no significant difference for the slopes between the dose groups.
Differences in Myelin Pathology Correlate with Disease Severity
Previous reports have shown significant decreases in myelin basic protein immunoreactivity in sciatic nerves of mice with EAN that had been immunized with P0 180-199 (7) . The present study is the first to characterize the extent of myelin pathology via assessing myelin ultrastructure 54 days p.i. We found that all EAN mice displayed significant reductions in myelin thickness (as evident by increased G-ratios, indicating remyelination), and, therefore, that inflammatorymediated demyelination is a feature of this disease. Through the assessment of mean G-ratios, regression analysis of G-ratios in relation to axonal diameter and plotting G-ratio frequency distributions, we determined that animals induced with high Ptx doses had significantly thinner myelin compared with animals induced using low Ptx doses. Thus, the extent of demyelination was greater in the high dose versus low dose Ptx group, as well as compared with control mice.
Assessments of mean axon diameter revealed that mice induced with a high dose of Ptx had significant decreases in mean axon diameters compared with low dose Ptx and healthy controls; however, there was no significant difference in mean axon diameter between low dose Ptx and healthy control groups. Moreover, we observed tomaculous swellings and tomaculous neuropathy in all mice with EAN, although this was more obvious in the high dose Ptx groups. We did not Mutations in myelin protein zero gene (P0 gene) give rise to the peripheral neuropathies Charcot-Marie-Tooth, Déjerine-Sottas syndrome, and congenital hypomyelinating neuropathies (23) (24) (25) , and animal models of these diseases have been generated by genetically perturbing P0 (26, 27) . Interestingly, tomaculous neuropathy is a feature of these diseases; it is observed in the animal models; and it represents another form of pathology that can alter nerve conduction (26, 27) . Therefore, the finding of tomaculous neuropathy in this P0-mediated EAN model is not surprising. Indeed, it may serve as ancillary evidence that the induced inflammatory attack disrupts the functionality of the P0 protein and possibly explains the pathological findings. Moreover, dysfunction in proprioception is associated with tomaculous myelin and it is possible that the functional defects observed in this EAN model could be at least partly due to this kind of pathological mechanism. It is also known that both tomaculous neuropathy and demyelination have been associated with a reduction of axon diameter (22, 28) . Because we observed both higher G-ratios and a greater degree tomaculous neuropathy in the high dose compared with low dose Ptx cohorts, this may provide an explanation for the significantly reduced axon calibers observed in these mice. Another histopathological feature observed in all mice with EAE was dysmyelinated, or un-myelinated axons with myelin debris either touching or in very close proximity to axons (Fig. 5) . This is the first time that this has been reported in murine EAN and suggests that there is on-going degeneration and possibly demyelination even at 54 days p.i. This ongoing damage could account for the continued hind limb gait widening, decrease in running capacity and apparent lack of recovery in these functional measures.
Ptx Doses During Induction Influence Disease Severity
Previous reports have demonstrated the necessity for Ptx when using either P0 [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] or P0 106-125 peptides to induce EAN (7, 9) . Omitting Ptx from the EAN induction protocol using P0 [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] , results in a reduction in the percentage of mice that demonstrate clinical signs (7). We found that halving the Ptx dose during the induction paradigm did not affect the percentage of mice that displayed disease (Supplementary Data  Fig. S1 ). However, irrespective of the delivery method (i.p. or i.v.), mice that received a high dose of Ptx displayed significantly higher clinical scores, earlier failure in the running task and significantly and less myelin at 54 days p.i. We can only speculate on the mechanisms of Ptx dose effects. Ptx plays a role in promoting lymphocytosis and preventing T-cell unresponsiveness (29) ; it also enhances severity of other inflammatory mediated models of demyelination (30) (31) (32) (33) . For mice induced with a high dose of Ptx, failure in the running task was observed as early as 6 days post the first immunization, compared with 23 days as the earliest failure in the low dose Ptx groups. This was surprising because 6 days would not be sufficient time for a major adaptive immune response to take effect. Although it is likely that a higher dose of Ptx may alter the adaptive immune response to account for some differences in disease severity, it seems to be an unlikely mechanism influencing the early onset of running failure. Because Ptx transiently disrupts barrier function and vascular permeability (34, 35) , it is tempting to speculate that animals inducted with a high dose of Ptx may have been subject to more severely Mild limb paresis-in walking on a flat surface mice drag their belly on the ground, this is corrected in running and no belly dragging is observed when the mice run 3
If the animal displays with either, or any of the following: Tail paresis þ mild ataxia-tail paresis was assessed with the tail stroke test, and mice with mild ataxia displayed difficulty in walking Mild limb paresis þ mild ataxia-see above Limb paresis-in walking on a flat surface mice drag their belly on the ground, in running mice drag there belly on the ground and do have the limb strength to lift their belly off the ground (Supplementary Data Video S3) 4 If the animal displays with either, or any of the following: Limb paresis (including mild paraparesis) þ severe ataxia-mice with severe ataxia demonstrated though backward walking Tail paresis þ severe ataxia-see above (Supplementary Data Video S1) FIGURE 6. Continued different experimental groups indicate that all EAN groups displayed right-shifted distributions compared with healthy controls; however, the effect is more obvious for high dose Ptx groups. (E) Frequency distributions of myelinated axon diameters for different experimental groups, indicating that all EAN groups displayed a decrease in the distribution of large diameter axons, however, the effect is most obvious for the high dose Ptx groups.
disrupted the blood nerve barriers during induction. Future experiments are required to investigate the mechanism by which increasing the dose of Ptx alters early and late stage disease severity in this EAN model. In summary, we have extensively examined the murine EAN model induced by the P0 [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] peptide and have identified novel disability-based parameters that can be used as sensitive measures of disease severity. We performed detailed characterization of myelin ultrastructure and axonal caliber and demonstrate that thinner myelin and tomaculous neuropathy are features of this model. This study also revealed that the dose of Ptx during EAN induction is able to influence disease severity and the extent of myelin pathology. Thus, this study further supports the notion that EAN is a powerful animal model of human peripheral demyelinating polyradiculoneuropathies, thereby paving the way for studying pathogenesis and determining the efficacy and mechanisms of putative therapies that target remyelination and protect against nerve damage using transgenic mice.
